Podcasts about jnj

Dale Smothers says it's a “powerful thing” that traders aren't running to the bond market for safety. “I believe this is all due to the optimism” around the America First agenda of the Trump administration. He thinks the S&P 500 will finish the year around 6,500, citing pent-up demand and $7T “on the sidelines.” He argues that the market is broadening beyond tech, “a very good thing,” and he would love to see “consumer discretionary climbing a little bit higher.” His picks include AMZN, AAPL, and JNJ.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-...Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-...Watch on Sling - https://watch.sling.com/1/asset/19192...Watch on Vizio - https://www.vizio.com/en/watchfreeplu...Watch on DistroTV - https://www.distro.tv/live/schwab-net...Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Did you buy the dip? Do you know how to use the tools you have? Here are AI hacks to use! ⁠⁠⁠⁠⁠GET THE TRENDSPIDER SALE HERE BEFORE IT ENDS⁠⁠⁠⁠⁠Here are the links to all the sales: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Seeking Alpha Premium⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠:  with a 7-day free trial—save $30⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SAVE ON TRENDSPIDER - GET THE ANNUAL SUBSCRIPTION TO GET MY 4 HOUR ALGORITHM ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de #NoHayDerecho abordaremos, entre otros temas: -La #JNJ amenaza a #DeliaEspinoza con usar la “fuerza pública” si no repone a #PatriciaBenavides. - El #SecretarioGeneraldelaJNJ pone en conocimiento del #Congreso resolución en caso #PatriciaBenavides. - La #JuntadeFiscalesSupremos pide a la #JNJ precisar cómo se repondrá a #PatriciaBenavides si #DeliaEspinoza ya es #FiscaldelaNación. - La #JNJ convoca a una reunión entre #DeliaEspinoza y #PatriciaBenavides. - Admiten #amparo presentado por #DeliaEspinoza contra regreso de #PatriciaBenavides como #FiscaldelaNación: audiencia será el 8 de agosto. - La #FederaciónLatinoamericanadeFiscales respalda la permanencia de #DeliaEspinoza como #FiscaldelaNación. - Exclusiva: peruanos pagarán defensa legal de #JuanJoséSantiváñez en otro caso.

Aldo Vásquez, exmiembro de la JNJ , conversa con Glatzer Tuesta en No Hay Derecho de Ideeleradio. No Hay Derecho en vivo de lunes a viernes, desde las 7 a. m., por el YouTube y Facebook de Ideeleradio.

Magistrado de la JNJ denuncia que la misma institución le hace reglaje y confirma TODAS las irregularidades cometidas para favorecer a Patricia Benavides. En Piura, un escolar le dio a Dina clases de cómo gobernar; Y pronto en Lima: los drones kamikazes.

Inés Tello, expresidenta de la JNJ, conversa con Glatzer Tuesta en No Hay Derecho de Ideeleradio. No Hay Derecho en vivo de lunes a viernes, desde las 7 a. m., por el YouTube y Facebook de Ideeleradio.

La fiscal de la Nación, Delia Espinoza, presentó un hábeas corpus ante una posible detención, tras el intento de Patricia Benavides de tomar por la fuerza la Fiscalía con apoyo de la JNJ. El Gobierno toma partido y apoya el retorno de Benavides.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Eduardo Salhuana intenta justificar visitas de mineros informales: “El Congreso es una institución de puertas abiertas”. - Comisión de Ética recomienda investigar a Susel Paredes por uso de baños del Congreso por personas transexuales. - Pleno del Congreso abordará mociones de censura contra Gustavo Adrianzén el próximo miércoles 14 de mayo. - Fiscalía sobre extinción de dominio: “Se debilita lucha contra la corrupción, crimen organizado, lavado de activos y delitos medioambientales”. - ONU DD. HH. expresa su preocupación por modificaciones a la Ley Apci y la CIDH pide al Gobierno derogarlo. - Relatora de la ONU alerta sobre hostigamiento y amenazas contra la suspendida fiscal Marita Barreto. - Junta de Fiscales Supremos expresa su rechazo a promulgación de modificatoria de la extinción de dominio. - Congresista Jorge Montoya se burla del aniversario del Ministerio Público e insiste en vincular al IDL y a Gustavo Gorriti con dicha institución. - 'Cuchillo', sindicado por asesinato múltiple en Pataz, envió carta notarial a la presidenta Dina Boluarte. - Presidenta Dina Boluarte: sentamos las bases de un nuevo modelo económico que trae crecimiento y empleo. - Excongresista Cayo Galindo juró como nuevo integrante de la JNJ. - Exclusivo: Gobierno pretende eliminar 14 programas de infraestructura.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de #NoHayDerecho abordaremos, entre otros temas: - Dina Boluarte pide a la JNJ evaluar y sancionar a fiscales y jueces que liberan delincuentes. - Nuevo aeropuerto Jorge Chávez: colocan muros de dos metros en Av. Morales Duárez para “mejorar” la imagen de ingreso al terminal. - Fiscal de la Nación remueve a fiscal que investigaba muertes durante las protestas contra Dina Boluarte. - Asociación de familiares de desaparecidos critica leyes aprobadas por el Comgreso en materia de DDHH. - Amnistía Internacional: leyes aprobadas por el Congreso ponen al Perú en un "escenario de alto riesgo" para los DD.HH. - Fuerza Popular, Avanza País, APP y otros 28 partidos presentaron firmas falsas para inscribirse en elecciones, según Reniec. - Red de sobrevivientes del Perú rechaza la participación de Juan Luis Cipriani en las reuniones previas al cónclave por estar suspendido de sus funciones. - Eduardo Salhuana defiende permanencia de Yessenia Lozano. - Exclusivo: Las visitas a Yessenia Lozano.

So when Lauren invited Heather Campain, VP, CPG Integrated Go-to-Market Strategy at Epsilon, onto the podcast I immediately went to her LinkedIn, and here's what I saw below her name: Unified Commerce Leader | Silo Slayer | Possibilist | Omni Integration | eComm| Marketing | Retail Media | Joint Value Realization | JBP | Product Dev | Data+Analytics | Transformation. That plus 10 years at JnJ, Head of Strategy for the Walmart Business at Pepsico, and now at Epsilon. I thought “this is going to be good.” And it was.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: Papa Francisco, primer pontífice latinoamericano, fallece a los 88 años. Dina Boluarte vuelve a beneficiar a Wilfredo Oscorima: transfiere 49 millones de soles a obra que ya fue financiada. Juan José Santiváñez ganará más de S/17.000 mensuales a cargo de la nueva oficina del Despacho Presidencial. Caso Medifarma: suero mortal cobra su séptima víctima y Congreso no interpelará al ministro de Salud. -Minsa rechaza financiamiento del Banco Mundial y sale en defensa de funcionaria. Delia Espinoza envió a la JNJ denuncia de José Domingo Pérez contra Juan Fernández Jerí. Expreso y Alejandro Aguinaga atacan a fiscal José Domingo Pérez con supuesta enfermedad de salud mental. Susana Villarán: sala resuelve apelaciones que venían dilatando el inicio del juicio de la exalcadesa. Fiscalía no pudo verificar veracidad de audio contra Marita Barreto. Denuncian millonarias órdenes de servicios del Mininter en personal trainer para sus trabajadores, evento deportivo y más. Jorge Montoya usa caricatura sin firma para decir mentiras sobre 'Carlincaturas' de La República. Organismos internacionales expresan su preocupaciób por promulgación de la Ley Anti ONG. Exclusivo: El Congreso y cómo se gestó la Ley Anti ONG.

This week, Nathan from Dividend Watch joins us to discuss everything from high-yield strategies to sustainable yields, the psychology behind investor decisions, and even the impact of global tariffs. Plus, hear our thoughts on companies like Johnson & Johnson, Broadcom, and many more.Tickers mentioned: JNJ, AVGO, SCHD, VYM, AT&T, JEPQ, JPI, LVMH, ASML, NOVO, UN, SAP, IBM, BRBY, META, GOOG, MSFT, AAPL, SHEL, AGG, BTI.Site: https://dividend.watchLinkedIn: https://www.linkedin.com/in/nathan-hamilton-8492456/

S&P Futures are moving higher mainly due to optimism on tariff exemptions. The Trump tariff narrative remain the key focus as the White House indicates that that it is looking to help the auto sector. Pharma & semiconductor stocks are on watch as they are under review by the Trump tariff team. China has suspended jet deliveries from Boeing in retaliatory move. U.S. trade officials met with EU's trade representative yesterday, the demands from the Trump administration will be difficult for the Eurozone to agree to. Mining stocks are displaying gains due to a report that indicates President Trump has plans to stockpile critical metals to counter China. On the economic calendar today are reports on Import Exports prices and the Empire state Manufactuing index. JNJ, BACPNC & ERIC are higher after earnings announcements. Caterpillar named a new CEO.

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: Murió Mario Vargas Llosa: el nobel de literatura dejó de existir a los 89 años en Lima. Subcomisión de Acusaciones Constitucionales archiva denuncia constitucional contra Dina Boluarte por caso Rólex. Subsistema Nacional Especializado en Extinción de Dominio advierte que 5 mil casos tendrían que archivarse con ley del Congreso. Lima y Callao se desangran: Matan 10 personas en menos de 24 horas. Gobierno prohíbe que motociclistas viajen con acompañante y amplía estado de emergencia en Lima y Callao. Autoridades del Estado firman acta de compromiso en materia de seguridad ciudadana realizado en el Congreso. Datum: El 79% cree que situación seguirá igual o peor con el nuevo ministro del Interior. Quedan 43 partidos habilitados para las elecciones generales del 2026. Alfonso López Chau renunció al cargo de rector de la UNI para iniciar su campaña presidencial. Alejandro Cavero ve con buenos ojos la candidatura de Phillip Butters a la presidencia por Avanza País. Exoperario de Medifarma rompe su silencio y asegura que lo incriminaron: “Me obligaron a firmar una carta”. Sociedad Civil cuestiona la Ley Anti ONG apronada por el Congreso. Exclusivo: Los procesos abiertos de Antonio Fernández Jerí en la JNJ.

US equities saw S&P 500 going down 0.33% and Nasdaq with modest gains as worries about 20% universal tariffs and stagflation concerns surrounding the ISM manufacturing print remained overhangs. Treasury yields were flat overnight, gold higher and crude lower. The dollar index was flat, Bitcoin futures were up 3.4%. The overall performance of Asian Equity market was directionless, with no major benchmark moving higher or lower by more than 0.5%, European equity markets opened lower, following broad strength on Tuesday. Companies mentioned: JNJ, Boeing, Andreesen Horowitz, Becton Dickinson, Qualcomm

S&P Futures are displaying weakness this morning as the markets continue to await clarity on the tariff situation. U.S. auto manufactures are making a push to exclude certain car components from tariffs. President Trump is expected to sign Executive Orders today related to national security and economic policy. There is a press conference today at noon. Key economic reports due out today on the ISM Manufacturing and JOLT's data. A Texas court rejected JNJ use of Chapter 11 for its talc cancer fund. PVH and PRGS are higher this morning after earnings releases.

Today, we share our five top stocks to buy if they won thelottery, including picks like Pernod Ricard, Visa, Ferrari, Microsoft, and LVMH. With no restrictions, such as yield, we look at key factors driving our choices, such as brand power, growth potential, and pricing strength.We also preview an upcoming newsletter on big pharma, with Derek focusing on Merck & Co. and the top-selling drug, Kuda.And as always, we finish with some excellent Listener questions

Hey everyone, and welcome back to Dividend Talk! In this episode, we look into the latest market corrections and explore exciting stock opportunities. We chat about Intel's new CEO, the football matches that had us on the edge of our seats, and some fantastic dividend announcements from companies like Legal and General and Henkel. Plus, we answer your insightful questions on portfolio strategy, handling market volatility, and killer criteria for your holdings. Tickers Mentioned: INTC, V, O, SHEL, ASR, EPI, MSFT, EVVTY, SBUX, PEP, V, LGEN, SPX, MMM, RHM, JNJ, XOM, TGT, HD, WMT, GLB, CILA, TRP, GOOG, ASML, BA, MUM.

El Congreso ataca a la Fiscalía con denuncias contra Delia Espinoza. El Tribunal Constitucional anula sanciones de la JNJ, beneficiando a magistrados destituidos. Nuevo papelón de la PNP; y Keiko empezó su campaña reviviendo la teoría del fraude.

The Olympics. The World Cup. The Super Bowl. These competitions bring the world together to back their favorite teams as they compete for the ultimate title. But March Market Cap Madness has an even bigger draw, because you not only get to root for your favorite; you get to compete! Strap in and get your pencils ready, it's go time! Companies discussed: DAVA, DUOL, GXO, UA, JNJ,  SMMT, AX, ROKU, DDOG, IOT, FICO Host: David Gardner Guests: Andy Cross, Matt Argersinger Producer: Rick Engdahl

Pursuing social anxiety disorder with MDMA. Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds (1:30). Standing on the shoulders of Johnson & Johnson's Spravato (4:00). Upcoming milestones and clinical trials (13:15). Psychedelic industry sentiment; RFK Jr influence (30:40).Show Notes:Psychedelic Stocks: Focus On Their CashDeep Dive: Atai Life SciencesFDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks UnchangedRead our episode transcriptsFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

La fiscal de la Nación advirtió que cambios en la Ley de Extinción de Dominio que aprobaría el Congreso favorecería a corruptos y prófugos. René Boluarte, hermana de Dina, es asesora de la JNJ. Y la gobernante expresó su sorpresa por las lluvias en el país.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Policía separó solo por inasistencias a suboficial investigado por muerte en protestas. - Dina Boluarte envía carta notarial a la Clínica Sanna para evitar que entreguen su historial clínico a la Fiscalía. - Adrianzén dice que colapso del Puente Chancay era previsible por su antigüedad. - JNJ confirma apertura de procedimiento disciplinario contra Janet Tello y 4 jueces supremos y asegura respeto al debido proceso. - Janet Tello califica de apresurado el proceso disciplinario en su contra en la JNJ. - Millonario buffet en el Congreso: nuevo contrato de alimentos costará 1.6 millones de soles. - Alejandro Muñante y Fernando Rospigliosi piden que Cancillería solicite información al gobierno de EE. UU. sobre financiamiento de Usaid en el Perú. - Rafael López Aliaga admite que no podrá cumplir su promesa de adquirir 10 mil motos para Lima. - Exclusiva: Mateo Castañeda y la municipalidad de Comas.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Niños le recuerdan a Dina Boluarte el caso Rolex y los almuerzos a 10 soles durante Carnaval Ayacuchano. - Rafael Dumett: Hay una guerra declarada por fuerzas autoritarias aliadas con intereses corruptos. - Rafael López Aliaga admite que si votó a favor de otorgarle peajes a OAS en 2009. - Janet Tello, presidenta del Poder Judicial, califica como “preocupante” que JNJ le abra proceso disciplinario. - JNJ admite denuncia contra Delia Espinoza interpuesta por Juan José Santiváñez. - Dina Boluarte seguirá siendo investigada por el Caso ‘Cofre’: PJ rechaza recurso de la presidenta. - Javier González Olaechea quiere ser presidente e invitar a Elon Musk al Perú. - Trump suspende una ley que prohíbe el soborno por parte de funcionarios extranjeros. - Exclusiva 1: Rafael López Aliaga y los pagos a su asesor. - Exclusiva 2: Más prohibiciones para postular al Congreso.

En esta edición de No Hay Derecho abordaremos, entre otros temas: - Mincul modifica las condiciones para autorizar presentaciones de espectáculos en el Gran Teatro Nacional. - Por segunda vez, Dina Boluarte espera que una mujer sea la próxima presidenta del Perú. - Janet Tello pidió al Congreso restituir la detención preliminar en casos de no flagrancia. - JNJ alista suspensión de la presidenta del Poder Judicial Janet Tello. - Fuerza Popular usa las instalaciones del Congreso para que abogado cuestione la labor de los fiscales del Equipo Lava Jato. - MTC confirma inicio de pruebas en el nuevo aeropuerto y ratifica inauguración para el 30 de marzo. - Augusto Álvarez Rodrich pide a los medios de comunicación ser más transparentes con el dinero que reciben.

This week Russ talks with Dr. Robert Ramsey who runs the Facebook group Dentistry Gone Wild which offers a humorous non-political take on dentistry that we all often need in the world of dental facebook.  We talk for the hour about Robert's journey from JnJ to dentistry, and why we both left Corporate America to go do dentistry.  Robert talks about the DSOs he works for and his experience doing HMO dentistry (spoiler alert: it isn't all that bad).  Finally we discuss refunds and specialists.  

In this episode, we explore where value might be hiding in today's high-valuation market. From overlooked oil and gas plays to global opportunities in Japanese railways and Chinese big tech, we break down areas of potential interest for savvy investors. We also discuss the pitfalls and potential in pharma, defense, and precious metal miners, as well as the challenges pandemic darlings face in a post-COVID world. Plus, Braden dives into the concept of quality in investing, inspired by Dev Kantesaria of Valley Forge Capital. Discover why the intersection of growth and predictability defines great companies and how this framework can help you identify enduring opportunities in any market environment. Tickers of Stocks/ETFs discussed: HAL, TVK.TO, CNQ.TO, TOU.TO, ENB.TO, TRP.TO, KMI, MPC, JNJ, PFE, MRK, LLY, NVO, KVUE,PPH, IHE, ZHU.TO, LMT, UNP, 9020, KWEB, BABA, FNV.TO, WPM.TO, ABX.TO, NGT.TO, GDX, GDXJ, ZGD.TO, DOO.TO, 7309 Check out our portfolio by going to Jointci.com Our Website Canadian Investor Podcast Network Twitter: @cdn_investing Simon’s twitter: @Fiat_Iceberg Braden’s twitter: @BradoCapital Dan’s Twitter: @stocktrades_ca Want to learn more about Real Estate Investing? Check out the Canadian Real Estate Investor Podcast! Apple Podcast - The Canadian Real Estate Investor Spotify - The Canadian Real Estate Investor Web player - The Canadian Real Estate Investor Asset Allocation ETFs | BMO Global Asset Management Sign up for Finchat.io for free to get easy access to global stock coverage and powerful AI investing tools. Register for EQ Bank, the seamless digital banking experience with better rates and no nonsense.See omnystudio.com/listener for privacy information.

Join the European Dividend Growth Investor (EDGI) and Derek as we dive into the latest financial news and dividend company earnings. In this episode, we analyse Signify's dividend hike, Johnson & Johnson's earnings, and Texas Instruments' financial struggles. We also talk about topics like the "Income Factory" investment strategy, currency diversification, and the risks of covered call ETFs. Finally, EDGI shared highlights from the Utrecht Dividend Day Mentioned Tickers:PHG, JNJ, PG, UL, TXN, QCOM, NKE

Escucha aquí la opinión de Glatzer Tuesta, conductor del programa No Hay Derecho. En esta edición de No Hay Derecho abordaremos, entre otros temas: - Comisión de alto nivel de la OCDE exhorta al Perú a proteger la independencia judicial y fiscal. - Pleno de la JNJ impuso segunda destitución a Patricia Benavides como fiscal suprema, pero la absuelve por cambios en casos. - Ministro de Defensa denuncia que PNP aún no presenta plan operativo para que militares salgan a las calles en Trujillo. - Inasistencias salvan a congresista: Comisión de Ética no evaluó el caso de José Jerí por falta de quórum. - Policías mintieron: Darwin Condori sí estuvo en comisaría el día que hallaron a joven asesinada. - Rafael López Aliaga usa actividad municipal para cuestionar a la izquierda peruana. - Difunden video de Milagros Leyva dando indicaciones a Yaziré Pinedo sobre cómo responder en entrevista. - Exclusiva: Falsa inauguración de salas en Hospital Loayza.

S&P Futures are moving higher this morning with positive momentum in tech stocks. The tech rally is due to a White House announcement on the Stargate Project which is $500B fund to build out AI infrastructure. Concerns over tariffs are falling, while Trump has spoken about plans to impose 25% tariffs on Feb 1 on goods from Mexico & Canada, the trade deficit study is schedule for April 1st. Earnings are also in focus today with NFLX, IBKR & JNJ moving higher after releasing their reports. European shares are showing gains & oil prices are higher by +0.25% this morning.

S&P Futures are trading higher as the market react to a new administration in the White House. The President's ability to issue Executive Orders will be on watch this week with possible tariff announcement on Canada and Mexico. Earning reports will be in focus this week ahead as a host of major companies are scheduled to release. MMM reported a beat this morning and after the bell today NFLX, STX & UAL will report. Tomorrow morning, PG, JNJ, ABT, TRV & HAL will be releasing earnings reports. Davos conference is underway, President Trump is expected to remotely address the forum on Thursday. European shares are starting to pull back & oil prices are down more than -1.5% this morning.

In this episode of Dividend Talk, we dive into the world of dividend-focused ETFs available to European investors. In the News of the Week, we explore the recent sharp decline in Greggs' share price following its trading update, despite record sales. Is this an opportunity to buy, or should investors look elsewhere? The Listener Questions segment tackles a range of intriguing topics: How to prioritise investments when building a dividend portfolio. Why many REITs show negative ROIC vs WACC differences. Expectations for organic growth in diversified dividend portfolios. A thought experiment involving a €50,000 inheritance and turnaround companies. Finally, we wrap up with stock-specific discussions, including Schneider Electric, PepsiCo, and Eaton, while addressing questions on private equity, T. Rowe Price, and Sonoco Products.

Aldo Vásquez, expresidente de la JNJ, conversa con Glatzer Tuesta en No Hay Derecho de Ideeleradio. No Hay Derecho en vivo de lunes a viernes, desde las 7 a. m., por el YouTube y Facebook de Ideeleradio.

In this podcast I explain reasons why I would invest in JNJ right now, but then also will share reasons why I wouldn't, in hopes of presenting an unbiased analysis of a stock I'm long in. Join the world's largest free Dividend Discord ➜ https://discord.gg/kkSr5FY Join my channel membership as a GenEx Partner to access new perks: https://www.youtube.com/channel/UCuOS-UH_s4KGhArN6HdRB0Q/join Seeking Alpha Affiliate Referral Link ➜ https://www.sahg6dtr.com/2352ZCK/R74QP/ Click my FAST Graphs Link (Use coupon code AFFILIATE25 to get 25% off your 1st payment) ➜ https://fastgraphs.com/?ref=GenExDividendInvestor Please use my Amazon Affiliates Link ➜ https://amzn.to/2YLxsiW Thanks! As an Amazon Associate I earn from qualifying purchases. Support me & get Patreon perks ➜ https://www.patreon.com/join/genexdividendinvestor My Financial Modeling Prep affiliate link for awesome stock data (up to a 25% discount) ➡️ https://site.financialmodelingprep.com/pricing-plans?couponCode=genex25

S&P Futures are positive this morning as earning reports start to hit the tape. BAC, JNJ & PNC are moving higher after their releases. Israel indicates that they will likely stick to military targets in their expected retaliatory strike on Iran. Boeing reaches a line of credit worth 10B with a group of banks. Google and Kairos Power working on a nuclear power project to supply its data centers with clean energy. In Europe, markets are mixed to lower with this week's ECB announcement in focus. Oil prices are displaying significant weakness this morning as oil prices fall more than -4% in the pre-market on news reports that Israel will not target Iran energy facilities.

Aldo Vásquez, miembro de la JNJ, conversa con Glatzer Tuesta en No Hay Derecho de Ideeleradio. No Hay Derecho en vivo de lunes a viernes, desde las 7 a. m., por el YouTube y Facebook de Ideeleradio.

Pedro and Tom discuss Intel being approached by Qualcomm about a takeover, JNJ files chapter 11 for the third time, and Microsoft partnering with Constellation Energy to reopen the Three Mile Island Nuclear Generating Station.For information on how to join the Zoom calls live each morning at 8:30 EST, visithttps://www.narwhalcapital.com/blog/daily-market-briefingsPlease see disclosures:https://www.narwhalcapital.com/disclosure

These violent delights have violent ends. Between 1992 BCE and 1941 BCE, King Montu-Hotep (“Montu is Content”) ruled the southern kingdom. And he led efforts to expand Theban power, and ultimately reunify the Two Lands… Logo image: Montu, in a chapel of Ramesses III at Karnak (Kairoinfo4u). Website: www.egyptianhistorypodcast.com. Support the show via Patreon www.patreon.com/egyptpodcast. Make a one-time donation via PayPal payments. Music and interludes by Keith Zizza www.keithzizza.net. Music and interludes by Luke Chaos www.chaosmusick.com. Montuhotep's Expansion into Wawat / Nubia and the records of the wars: Darnell, ‘The Route of the Eleventh Dynasty Expansion into Nubia: An Interpretation Based on the Rock Inscriptions of Tjehemau at Abisko', Zeitschrift für Ägyptische Sprache und Altertumskunde 131 (2004), 23—37. Available on Academia.edu. Darnell, ‘The Eleventh Dynasty Royal Inscription from Deir el-Ballas', Revue d'Égyptologie 59 (2008), 81—110. Available on Academia.edu. Montuhotep's Mahat Chapel at Abydos, discovered in 2014: Josef Wegner at Academia.edu and Damarany in Abydos: The Sacred Land (2019), JSTOR. Scholarly debates on the timeline and events of the Reunification: Brovarski, ‘The Hare and Oryx Nomes in the First Intermediate Period and Early Middle Kingdom', in Egyptian Culture and Society: Studies in Honour of Naguib Kanawati, 1 (2010), 31—85. Available on Academia.edu. This was the study I followed in my reconstruction. Willems, ‘The Nomarchs of the Hare Nome and Early Middle Kingdom History', Jaarbericht van het Vooraziatisch-Egyptisch Genootschap Ex Oriente Lux 28 (1985), 80—102. Available at Researchgate. Nubia – The Archaeology of Wawat and Kerma: Kerma – Mission archéologique suisse à Kerma (Soudan) C. Bonnet, ‘The Cities of Kerma and Pnubs-Dokki Gel', in G. Emberling and B. B. Williams (eds), The Oxford Handbook of Ancient Nubia (Oxford, 2021), 201—212. H. Hafsaas, ‘The C-Group People in Lower Nubia: Cattle Pastoralists on the Frontier Between Egypt and Kush', in B. B. Williams and G. Emberling (eds), The Oxford Handbook of Ancient Nubia (Oxford, 2020), 157—177. G. K. Meurer, ‘Nubians in Egypt from the Early Dynastic Period to the New Kingdom', in B. B. Williams and G. Emberling (eds), The Oxford Handbook of Ancient Nubia (Oxford, 2020), 289—308. B. B. Williams, ‘Kush in the Wider World During the Kerma Period', in G. Emberling and B. B. Williams (eds), The Oxford Handbook of Ancient Nubia (Oxford, 2021), 179--200. The Tomb of General Antef, with images of siege towers and naval forces: B. Jaroš-Deckert, Grabung im Asasif. 1963-1970. Band 5: das Grab des Jnj-jtj.f. Die Wandmalereien der 11. Dynastie, 12 (1984). Learn more about your ad choices. Visit megaphone.fm/adchoices

Cybin CEO Doug Drysdale talks to Jason Najum about transforming treatment of mental health disorders with psychedelics (0:45). CYB003, Phase 2 results for depression, moving into Phase 3 (3:00). How deuterated psilocin differentiates Cybin from competiton (10:00). IP and patents - critical to ROI (12:45). Esketamine and is JNJ's Spravato blazing a trail for psychedelics? (14:15) FDA challenges and Lykos lessons (21:20). Strong balance sheet will get it through Phase 3 data (25:50) Stock consolidation and attracting new buyers (30:35).Episode transcriptsShow Notes:Imran Khan On Psychedelics - More We Don't Know Than We DoPsychedelic Stocks: Focus On Their CashFDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks UnchangedDe-Risking Psychedelics: Compass Pathways, Cybin And AtaiFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

In this week's episode we'll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias.Featured Articles:CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemiaATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematologicalmalignanciesPreclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) inKMT2A- and NPM1-altered leukemias

S&P Futures are slightly positive as markets await this morning's employment data. On the earnings front, Broadcom will be releasing earnings after the bell today. Verizon reaffirms its 2024 guidance after announcing a $20B deal to take over Frontier Comm. JNJ appears to have settled the talc lawsuit by raising settlement offer by$1B. Jeep's parent Stellantis paused production of two of its top-selling U.S. models, as the company grapples with high inventory levels. In Europe, trading is mixed to lower. Oil prices are gaining this morning on the back of data for the American Petroleum Institute indicating a draw in stockpiles last night.

The CPG Guys are joined by Neel Arora, Global Head of eCommerce at Nestlé, the world's largest food & beverage consumer goods manufacturer. Joining PVSB in co-hosting this episode is FMCG Guys host Daniel Torres Dwyer.Follow Neel on LinkedIn at: https://www.linkedin.com/in/neel-arora-60912130/Follow Nestlé on LinkedIn at: https://www.linkedin.com/company/nestle-s-a-/Follow Nestlé online at: https://www.nestle.com/Listen to Neel's first episode of the CPG Guys podcast: http://cgguys.com/neelaroraNeel answers these questions:You took a sabbatical and were able to do so many things most wait until they are retired. How was the experience and what would you pass on to others?Let's stay on this topic, since it's not talked about most - tell us how you relaxed, made peace with your decision to recharge and what activities did you do to recharge? How did it feel to come back to work and adjust again into a routine at work?You lead global ecommerce for the world's largest food manufacturer, what is a day in the life of Neel?How does global leadership work? How many countries do you work with? How does a global team measure for success - what metrics do you create for accountability and how do you measure against it and ensure success for the consumer?How do you align country by country for outcomes at the digital shelf?Global capabilities - SCANR was how Sri thought about it at JnJ.  What's the latest with content? Does it make a difference any more in a digital creator economy? How do you integrate social commerce into what you do?As we wrap up this episode, let's talk trends - what are you keeping up with these days? What matters - AI, clean rooms, what else? CPG Guys Website: http://CPGguys.comFMCG Guys Website: http://FMCGguys.comCPG Scoop Website: http://CPGscoop.comRetailWit Website: http://retailwit.comRhea Raj's Website: http://rhearaj.comLara Raj on PopStar Academy: https://www.netflix.com/us/title/81587828?s=i&trkid=258593161&vlang=enKavita's podcast: Spotify   AppleDISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in this episode should be construed as advice from CPGGUYS, LLC or the individual author, hosts, or guests, nor is it intended to be a substitute for research on any subject matter. Reference to any specific product or entity does not constitute an endorsement or recommendation by CPGGUYS, LLC. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.

S&P Futures are positive this morning with gains in tech shares. Earnings are in focus today, last night report from TSM was positive, company raised guidance which is helping elevate the sector. this morning. Airline sector is weak as UAL & ALK guided lower yesterday. After the bell today NFLX is expected to report. Odds of President Biden leaving the race have increased over the last 24 hours. Also seeing earnings beats from ASML, JNJ, CFG & USB in the pre-market. Multiple Fed speakers today (Goolsbee, Logan & Daly) which will be their last comments before the July Fed meeting. In Europe, markets are higher ahead of an ECB announcement on monetary policy. Market anticipates two more rate cuts from the ECB this year. Oil prices are ticking lower as oil gives back some of yesterday's gains.

S&P Futures are giving back some of yesterday's big gains with tech shares falling this morning. Market is aggressively moving out of tech and into small caps. White House is looking at more restriction on tech sales by foreign companies. Five Below lowered its eps guidance and said that it's CEO is stepping down. Also seeing earnings beats from ASML, JNJ, CFG & USB in the pre market. In Europe, markets are lower as Trump talks up tariffs on foreign companies. Earnings remain a key factor today with AA, UAL and DFS to report after the bell. Oil prices have turning higher due to a draw in stockpile estimated for last night's API report. Stockpiles data will be monitored closely.

¡Buenos días! Empezó el juicio oral contra Keiko Fujimori, pese a la oposición de su abogada. Aquí todo lo que necesitas saber sobre el juicio que se puede prolongar por años. Vuelve la novela: El Poder Judicial ordena reponer a Inés Tello y Aldo Vásquez en la JNJ. ADEMÁS: Suboficial PNP fue víctima de doble abuso. Humedad en Lima: ¿Por qué en el invierno limeño NO llueve pero sí se llena el cielo de neblina? Nos lo explica Juan Carlos Sueiro, especialista de OCEANA Perú. **** ¿Te gustó este episodio? ¿Buscas las fuentes de los datos mencionados hoy? SUSCRÍBETE en http://patreon.com/ocram para acceder a nuestros GRUPOS EXCLUSIVOS de Telegram y WhatsApp. También puedes hacerte MIEMBRO de nuestro canal de YouTube aquí https://www.youtube.com/channel/UCP0AJJeNkFBYzegTTVbKhPg/join **** Únete a nuestro CANAL de WhatsApp aquí https://whatsapp.com/channel/0029VaAgBeN6RGJLubpqyw29 **** Para más información legal: http://laencerrona.pe

AL FIN, cayó alias "Vane". Les contamos qué hubo detrás de la insólita unanimidad de la JNJ en dos de los casos contra Patricia Benavides. MIENTRAS TANTO: Con Castillo y Vizcarra, bien. Con Dina, nunca. Gobierno plantea que ya no se pueda investigar a presidentes. ADEMÁS: El congresista ChatGPT. Y... ¿Cuántos grifos son bombas de tiempo en nuestro país? Vecinos de Surco nos escriben por un potencial caso. **** ¿Te gustó este episodio? ¿Buscas las fuentes de los datos mencionados hoy? SUSCRÍBETE en http://patreon.com/ocram para acceder a nuestros GRUPOS EXCLUSIVOS de Telegram y WhatsApp. También puedes hacerte MIEMBRO de nuestro canal de YouTube aquí https://www.youtube.com/channel/UCP0AJJeNkFBYzegTTVbKhPg/join **** Únete a nuestro CANAL de WhatsApp aquí https://whatsapp.com/channel/0029VaAgBeN6RGJLubpqyw29 **** Para más información legal: http://laencerrona.pe

Dan Nathan and Carter Worth break down the top market headlines and bring you stock market trade ideas for Tuesday, April 16th. Timecodes 0:00 - S&P 500 Technicals 13:00 - JNJ & AXP Trade IDea 26:45 - SLV Update 30:30 - Yields 36:00 - XLU Update Subscribe to our daily newsletter Subscribe to MRKT Call reminders & show notes MRKT Call is brought to you by our presenting sponsor Fidelity Watch MRKT Call LIVE at 1 pm M-TH on YouTube Follow us on Twitter @MRKTCall Follow @GuyAdami on Twitter Follow @RiskReversal on Twitter Follow @CarterBWorth on Twitter Follow us on Instagram @RiskReversalMedia Like us on Facebook @RiskReversal Watch all of our videos on YouTube Options Disclosure Agreement

Boeing CEO David Calhoun is stepping down – who can step in to fix the company's engineering woes and a culture issues? (00:21) Emily Flippen and Jason Moser discuss: - Boeing's hunt for a new CEO, and the difficulty of shifting company culture. - Big deals helping Home Depot corner the professionals market and Johnson and Johnson dive deeper into medtech. - McCormick's strong earnings, and Amazon's continued investment in AI. (19:11) Motley Fool Analyst Sanmeet Deo caught up with Elf Beauty CEO Tarang Amin about the beauty brand's social strategy and the unconventional ways it's scooping up market share from older competitors. (30:39) Jason and Emily break down two stocks on their radar: Masimo and Mastercard. Stocks discussed: BA, HD, JNJ, MKC, AMZN, ELF, LRLCY, RBLX, AAPL Host: Dylan Lewis Guests: Jason Moser, Emily Flippen, Sanmeet Deo, Tarang Amin Engineers: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices